Showing 5001-5010 of 7806 results for "".
- New Book Launched: Cosmeceuticals and Cosmetic Ingredientshttps://practicaldermatology.com/news/20141113-new_book_launched_cosmeceuticals_and_cosmetic_ingredients/2459067/"Cosmeceuticals and Cosmetic Ingredients" (McGraw Hill), the second textbook from Dr. Leslie Baumann, is now available through Amazon.com and booksellers internationally. Written for medical and skincare students and professionals, "Cosmeceuticals and Cosmetic Ingredients" focuses on the scien
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a
- Skin Cancer Foundation: Dermatologists and Beauty Professionals Team Up to Spot Skin Cancershttps://practicaldermatology.com/news/20141113-skin_cancer_foundation_dermatologists_and_beauty_professionals_team_up_to_spot_skin_cancers/2459069/The Skin Cancer Foundation is encouraging dermatologists and beauty professionals to work together through an education program called Heads Up! The skin cancer awareness program provides beauty professionals, including hair stylists and aestheticians, with tips on what to look for, and how to speak
- Promius Pharma Launches Promiseb Topical Cream 60 Gram Optionhttps://practicaldermatology.com/news/20141105-promius_pharma_launches_promiseb_topical_cream_60_gram_option/2459073/Promius Pharma LLC launched Promiseb Topical Cream in a new 60 gram box. This well-regarded non-steroidal cream for the treatment of seborrheic
- Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removalhttps://practicaldermatology.com/news/20141103-syneron_candela_announces_fda_clearance_of_picoway_picosecond_laser_for_tattoo_removal/2459076/The FDA granted 510(K) clearance to Syneron Candela's PicoWay picosecond device for tattoo removal. PicoWay is a dual wavelength device, with 1064nm and 532nm wavelengths, which utilizes the proprietary PicoWay Technology to generate picosecond pulses for the removal of tattoos. The FDA clearanc
- Foamix Pharmaceuticals Will Host Key Opinion Leader Meeting and Webcast on November 4th in New York Cityhttps://practicaldermatology.com/news/20141029-foamix_pharmaceuticals_will_host_key_opinionleader_meeting_and_webcast_on_november_4th_in_new_york_city/2459077/Foamix Pharmaceuticals Ltd. will host a Key Opinion Leader breakfast on Tuesday, November 4, 2014 from 8:00am-9:30am Eastern Time in New York City. The meeting will feature key opinion leader Mark Lebwohl, MD, who leads a renowned dermatology program in the U.S., as the Sol and Clara Kes
- FDA Advisory Committee Recommends Approval of Secukinumab for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/20141020-fda_advisory_committee_recommends_approval_of_secukinumab_for_moderate_to_severe_plaque_psoriasis/2459081/The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the FDA voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates
- Harvard Business Review Names Allergan's David E. I. Pyott a Top CEOhttps://practicaldermatology.com/news/20141015-harvard_business_review_names_allergans_david_e_i_pyott_a_top_ceo/2459084/David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, Inc., has been ranked the 4th best-performing CEO in the world by the Harvard Business Review (HBR). Mr. Pyott was selected for this honor out of a total o
- Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patientshttps://practicaldermatology.com/news/20141013-novartis_data_at_eadv_show_consistent_efficacy_of_ain457_secukinumab_in_clearing_skin_of_psoriasis_patients/2459087/Novartis announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1].
- SKINPACT Program Launched with New Global Awards Initiative to Support the Dermatology Communityhttps://practicaldermatology.com/news/20141010-skinpact_program_launched_with_new_global_awards_initiative_to_support_the_dermatology_community/2459088/Galderma, in partnership with the International League of Dermatological Societies, has started a search for initiatives that will fulfill an important role in strengthening the global dermatology community. Galderma launched a new global initiative un